AegirBio AB (AegirBio AB) Interest Expense : $-1.09 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is AegirBio AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AegirBio AB's interest expense for the three months ended in Mar. 2024 was $ -0.19 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AegirBio AB's Operating Income for the three months ended in Mar. 2024 was $ -0.89 Mil. AegirBio AB's Interest Expense for the three months ended in Mar. 2024 was $ -0.19 Mil. AegirBio AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AegirBio AB Interest Expense Historical Data

The historical data trend for AegirBio AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AegirBio AB Interest Expense Chart

AegirBio AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.46

-0.02

-0.98

AegirBio AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial													-0.01	-0.21	-0.71	0.02	-0.19

AegirBio AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.09 Mil.

AegirBio AB (GREY:AEGBF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AegirBio AB's Interest Expense for the three months ended in Mar. 2024 was $-0.19 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $3.36 Mil.

AegirBio AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

AegirBio AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

AegirBio AB (AegirBio AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AegirBio AB (GREY:AEGBF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AEGIR:Sweden 52Q:Germany

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.aegirbio.com

AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.

AegirBio AB (AegirBio AB) Headlines

No Headlines